Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics reports developments in cortisol modulation therapies for severe endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym for endogenous Cushing’s syndrome and Lifyorli, a relacorilant regimen approved with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
Recurring news includes financial results, revenue guidance, clinical data from programs such as ROSELLA, DAZALS and MOMENTUM, FDA-related updates, medical-conference presentations, publications, patent matters and distribution arrangements tied to Korlym, Lifyorli and the company’s selective cortisol modulator pipeline.
Corcept Therapeutics (NASDAQ: CORT) announces the appointment of Gillian M. Cannon, PhD to its Board of Directors. Dr. Cannon brings over 30 years of pharmaceutical experience, including leadership roles at Merck, UCB, and Otsuka. Her extensive experience in commercial operations is expected to support Corcept's pipeline of cortisol modulators. CEO Joseph K. Belanoff expressed confidence that her background will enhance the company’s ability to innovate in drug development.
Corcept Therapeutics (NASDAQ: CORT) announced that the U.S. Patent and Trademark Office's PTAB upheld the validity of U.S. Patent No. 10,195,214, which pertains to the co-administration of Korlym® with strong CYP3A inhibitors. The patent, expiring in 2037, supports the safe use of Korlym® alongside commonly prescribed medications for Cushing's syndrome patients. This discovery enhances treatment options for the approximately 20,000 U.S. patients suffering from this condition.
Corcept Therapeutics (NASDAQ: CORT) reported Q3 2020 results, revealing revenue of $86.3 million, a 6% increase year-over-year. However, GAAP diluted net income fell to $0.17 per share from $0.22 in Q3 2019, while non-GAAP net income decreased from $0.31 to $0.24 per share. The company's cash and investments rose to $444.2 million. A new $200 million stock repurchase program was announced, and 2020 revenue guidance was narrowed to $355 - 365 million. CEO Joseph K. Belanoff noted pandemic impacts on commercial results but expressed optimism for future growth.
Corcept Therapeutics (CORT) announced it will report its third quarter financial results on November 3, 2020. A corporate update will accompany the earnings report, alongside a conference call at 5:00 p.m. ET. To participate, attendees can register via a link or dial in using specified phone numbers. The replay of the call will be accessible until November 17, 2020. Corcept is focused on developing drugs for severe disorders by modulating cortisol's effects, with its approved drug Korlym® targeting Cushing’s syndrome, supported by a robust intellectual property portfolio.
Corcept Therapeutics (NASDAQ: CORT) has commenced the GRATITUDE II trial to assess miricorilant in obese patients with schizophrenia suffering from antipsychotic-induced weight gain. The study aims to enroll 150 participants, who will receive either miricorilant or placebo alongside their antipsychotic medication for 26 weeks. This follows the promising results of the Phase 1b trial, which indicated that miricorilant could reduce weight gain and liver enzyme levels in patients. This trial utilizes an enhanced formulation of miricorilant to build on previous findings.
Corcept Therapeutics reported strong financial results for Q2 2020, with revenue at $88.6 million, a 23% increase from Q2 2019. GAAP diluted net income rose to $0.23 per share from $0.17 YoY, while non-GAAP diluted net income also improved to $0.32 per share from $0.25. Cash and investments increased to $409.6 million. The company reaffirmed its 2020 revenue guidance at $355 million to $375 million, despite a slight revenue decrease compared to Q1 due to patient prescription shifts amid the COVID-19 pandemic.
Corcept Therapeutics (NASDAQ: CORT) will report its second quarter financial results and corporate update on August 4, 2020. A conference call will follow at 5:00 p.m. ET where participants can join by calling 1-800-353-6461 in the U.S. or 1-334-323-0501 internationally.
Corcept focuses on developing drugs that target cortisol effects for severe metabolic, oncologic, and psychiatric disorders. Its first product, Korlym®, is approved for Cushing’s syndrome. The company holds significant intellectual property related to its cortisol modulators.
Corcept Therapeutics (NASDAQ: CORT) has enrolled its first patient in the GRADIENT Phase 3 trial of relacorilant for Cushing's syndrome due to adrenal adenomas or hyperplasia. This double-blind, placebo-controlled study aims to include 130 patients in the U.S. and Europe, assessing glucose metabolism and hypertension over six months. Relacorilant, an innovative glucocorticoid receptor modulator, has already shown promise in the ongoing GRACE trial for various Cushing's syndrome causes. These initiatives could strengthen treatment options and drive market growth.
Corcept Therapeutics (NASDAQ: CORT) has completed patient enrollment in its Phase 2 trial of relacorilant combined with nab-paclitaxel for treating metastatic, platinum-resistant ovarian cancer. A total of 177 patients were enrolled across 28 sites in North America and Europe. The primary endpoint focuses on progression-free survival, alongside secondary measures like objective response rates. Following promising Phase 1/2 results, data from this trial are expected in the first half of the next year, positioning Corcept for potential advancements in its clinical portfolio.
Corcept Therapeutics (NASDAQ: CORT) has commenced the RELIANT trial, an open-label, Phase 3 study evaluating relacorilant in combination with nab-paclitaxel for treating metastatic pancreatic cancer. The trial aims to enroll 80 patients, with the primary endpoint being objective response rate. Interim data will be analyzed after the first 40 patients are enrolled. This follows encouraging results from a Phase 1/2 study presented at ASCO last year, indicating potential for accelerated approval if results are positive.